Merck Tbk PT banner

Merck Tbk PT
IDX:MERK

Watchlist Manager
Merck Tbk PT Logo
Merck Tbk PT
IDX:MERK
Watchlist
Price: 3 150 IDR -1.56%
Market Cap: Rp1.4T

Relative Value

The Relative Value of one MERK stock under the Base Case scenario is hidden IDR. Compared to the current market price of 3 150 IDR, Merck Tbk PT is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

MERK Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

MERK Competitors Multiples
Merck Tbk PT Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
ID
Merck Tbk PT
IDX:MERK
1.4T IDR 1.3 7.9 5.5 5.5
US
Eli Lilly and Co
NYSE:LLY
990.8B USD 15.2 48 32.3 34.4
US
Johnson & Johnson
NYSE:JNJ
590.6B USD 6.3 22 15.3 18.8
CH
Roche Holding AG
SIX:ROG
286.4B CHF 4.7 30.4 12.8 15
UK
AstraZeneca PLC
LSE:AZN
232.4B GBP 5.5 34.2 16.3 23.8
CH
Novartis AG
SIX:NOVN
236.9B CHF 5.4 21.8 13.4 17.2
US
Merck & Co Inc
NYSE:MRK
298.8B USD 4.6 16.3 10.2 11.9
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 333.1 835.4
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.3 9.8 11.5
US
Pfizer Inc
NYSE:PFE
157.2B USD 2.5 20.2 7.5 10
US
Bristol-Myers Squibb Co
NYSE:BMY
122.1B USD 2.5 17.3 6.8 8.7
P/E Multiple
Earnings Growth PEG
ID
Merck Tbk PT
IDX:MERK
Average P/E: 23.1
7.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
48
28%
1.7
US
Johnson & Johnson
NYSE:JNJ
22
7%
3.1
CH
Roche Holding AG
SIX:ROG
30.4
29%
1
UK
AstraZeneca PLC
LSE:AZN
34.2
38%
0.9
CH
Novartis AG
SIX:NOVN
21.8
15%
1.5
US
Merck & Co Inc
NYSE:MRK
16.3
14%
1.2
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
13.3
7%
1.9
US
Pfizer Inc
NYSE:PFE
20.2
26%
0.8
US
Bristol-Myers Squibb Co
NYSE:BMY
17.3
17%
1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
ID
Merck Tbk PT
IDX:MERK
Average EV/EBITDA: 42.1
5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
32.3
18%
1.8
US
Johnson & Johnson
NYSE:JNJ
15.3
2%
7.7
CH
Roche Holding AG
SIX:ROG
12.8
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
16.3
10%
1.6
CH
Novartis AG
SIX:NOVN
13.4
9%
1.5
US
Merck & Co Inc
NYSE:MRK
10.2
7%
1.5
IE
E
Endo International PLC
LSE:0Y5F
333.1
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9.8
7%
1.4
US
Pfizer Inc
NYSE:PFE
7.5
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
6.8
-13%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
ID
Merck Tbk PT
IDX:MERK
Average EV/EBIT: 90.2
5.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.4
17%
2
US
Johnson & Johnson
NYSE:JNJ
18.8
6%
3.1
CH
Roche Holding AG
SIX:ROG
15
6%
2.5
UK
AstraZeneca PLC
LSE:AZN
23.8
23%
1
CH
Novartis AG
SIX:NOVN
17.2
12%
1.4
US
Merck & Co Inc
NYSE:MRK
11.9
6%
2
IE
E
Endo International PLC
LSE:0Y5F
835.4
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
11.5
8%
1.4
US
Pfizer Inc
NYSE:PFE
10
-1%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.7
-6%
N/A